stockrow
Friday 6 November 2026
Export TOVX’s income statement to Excel — free account
Theriva Biologics, Inc.
TOVX Healthcare Biotechnology
- EPS
- +96.4%
- Free cash flow
- +34.7%
- Total debt
- −1.16%
Quarter to June 2026, against a year earlier
0.16
0.01
−5.88%
Follow TOVX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | — |
P/S ratio |
— | — | 0.00 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (3.34) | — | |
P/B ratio |
— | — | 0.53 | — | |
Price to Tangible BV |
— | — | 0.59 | — | |
EV/Sales |
— | — | 0.00 | — | |
EV/EBITDA |
— | — | 0.15 | — | |
EV/Operating CF |
— | — | 0.22 | — | |
EV/FCF |
— | — | 0.22 | — | |
Quick Ratio |
0.84 | 1.64 | 1.57 | 1.07 | |
Current Ratio |
0.90 | 1.74 | 1.63 | 1.13 | |
Net Debt/EBITDA |
1.33 | 5.59 | (0.77) | 2.97 | |
Debt/Assets |
5.36% | 4.37% | 4.25% | 4.65% | |
Debt/Equity |
0.25 | 0.11 | 0.11 | 0.13 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.99 | 0.82 | 1.20 | 0.96 | |
Capex/Depreciation |
(0.68) | 0.00 | 0.00 | (0.12) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 118.33% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 690.67% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 45.00% | 0.00% | |
Graham Net Nets |
— | — | (0.74) | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (1,274.75%) | — | |
Free Cash Flow Yield |
— | — | (175.35%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(0.45) | (0.10) | (0.06) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.45) | (0.10) | (0.06) | (0.07) | |
Cash per Share |
0.78 | 0.44 | 0.00 | 0.25 | |
Shareholders Equity per Share |
0.70 | 0.52 | 0.37 | 0.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.70 | 0.52 | 0.37 | 0.27 | |
Free Cash Flow |
(4.34) | (2.88) | (2.46) | (3.09) | |
Working Capital |
(1.10) | 7.45 | 6.49 | 1.56 | |
Capital Expenditures |
(0.02) | 0.00 | — | 0.00 | |
Net Current Asset Value |
(14.19) | (5.39) | (6.09) | (9.00) | |
EV/EBIT |
— | — | 0.15 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
1.78 | 3.29 | 8.86 | 1.70 | |
Average Payables |
0.78 | 0.94 | 0.52 | 0.80 | |
Average Assets |
35.47 | 36.80 | 35.20 | 35.34 | |
Average Common Equity |
15.69 | 17.23 | 15.45 | 11.41 |
Columns are period end dates · fundamentals updated 26 Oct 2026